Interview with Igor Krylov, CEO, Pharmstandard
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
Address: Likhachevsky drive 5 «B», Moscow region, Dolgoprudny, 141700,Russia
Tel: +7 (495) 970-0030/32
Web: http://pharmstd.ru/
Pharmstandard is the leader of Russian pharmaceutical industry in R&D and production of the medicinal products.
In 2010, Pharmstandard became №2 among all pharmaceutical companies represented in Russia and market share reached 4.2%.1 Since 2007 Pharmstandard keeps its leading position in commercial segment and remains strong leader among the domestic pharmaceutical company-manufacturers.*1
Pharmstandard became the winner of the national business award ‘Company of the Year 2010’ according to RBC.*2
During the tenth anniversary of «Platinum Ounce 2010», the open competition among professionals of pharma business, Pharmstandard was awarded in the nominations for «The Company of the Year – the Russian pharmaceutical products manufacturer» and «The Company of Decade – the Russian pharmaceutical products manufacturer».
Pharmstandard operates four modern pharmaceutical manufacturing facilities: JSC «Pharmstandard-Leksredstva» in Kursk, JSC «Pharmstandard-UfaVITA» in Ufa, JSC «Pharmstandard-Tomskhimpharm» in Tomsk, PJSC «Pharmstandard-Biolek» in Kharkov (Ukraine) and medical equipment factory JSC «TZMOI» in Tyumen.
The Company has invested approximately RUR 3 billion RUR in modernization and development of production capacities reaching more than 1,35 bln units per year. All the production facilities fully comply with Russian manufacturing standards. Six production lines of JSC «Pharmstandard-Leksredstva» meet EU GMP requirements.
Pharmstandard portfolio includes over 250 products used in the treatment of diabetes, growth hormone deficiency, cardiovascular diseases, gastroenterological and neurological disorders, infectious diseases, cancer. More than 100 products offered by Pharmstandard are included in the List of Vital and Essential Pharmaceuticals.
In 2004-1H2011, we developed and introduced over 55 new pharmaceutical products in close collaboration with the leading scientific centers of Russia. Pharmstandard is the partner of the joint venture biotechnological project «Generium» in order to develop and manufacture innovative biological products within the state program of import substitution.
Pharmstandard became a public company on 4 may 2007 by offering to the public 27.57% of its share capital in the form of GDR on the London Stock Exchange (LSE) and 18.12% of its share capital in the form of ordinary shares on two local stock exchanges (RTS, MICEX). Approximately 54.31%of voting shares of OJSC «Pharmstandard» are held by «Augment Investments Limited».
www.pharmstd.ru
1 Pharmexpert (CMR) 2010 market data.
2 The annual national business award ‘Company of the Year’ is organized by RBK Holdings.
Pharmstandard portfolio includes over 250 products used in the treatment of diabetes, growth hormone deficiency, cardiovascular diseases, gastroenterological and neurological disorders, infectious diseases, cancer. More than 100 products offered by Pharmstandard are included in the List of Vital and Essential Pharmaceuticals.
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
Although Russian authorities received heavy criticism for approving the Sputnik V vaccine prior to the completion of Phase III clinical trials, the jab is increasingly being seen as a viable…
Russia has announced that a domestically developed COVID-19 vaccine has been approved by its health authorities, the first such approval globally. However, with large-scale Phase III trials having not yet…
Below is a selection of top stories in Russian pharma from recent months, ranging from proposed changes in legislation, labelling system updates, priorities set forth by the country’s manufacturing association…
Russia is facing a drug shortage crisis which is having a particular impact on patients with life-threatening conditions. A combination of geopolitical and bureaucratic issues are restricting the flow of…
In the latest twist in the ongoing story of Russian interference in the US presidential elections of 2016, it has emerged that Russian internet trolls and automated bots spread misinformation…
In the United States, Johnson & Johnson has an image of being very close to people. Americans grow up with this company — from baby shampoo, to Tylenol when they…
The ARPM was founded in 2002, and you were its director from 2002-2004, before leaving for a post at the Roszdravnadzor. You’ve since rejoined as director since 2007. The organization…
When Focus Reports prepared a report on the French pharmaceutical industry in 2009/10, we found that the head of the main multinational pharmaceutical association had taken a career path quite…
The U.S. and Russia have a long history of trade, and you have personally been with the American Chamber of Commerce in Russia since 2001. Can you give a brief…
The primary objectives of this association are to promote Russia as a clinical trial destination, optimize the regulatory and legislative environment, and promote the interests of ACTO members. Can you…
You took over this organization just three months ago, having previously headed businesses in industries as diverse as retail, food, and automobiles. What drew you to Alliance Healthcare Russia? Do…
You have said that AstraZeneca intends to be “in Russia for Russia” and the company has recently announced a large-scale investment in this country, financing a $150Mn domestic facility in…
See our Cookie Privacy Policy Here